Search
Hutchison China MediTech Limited (Chi-Med) has successfully completed patient enrollment in the Phase III SANOVO study in China. This groundbreaking study explores the efficacy of combining Savolitinib (ORPATHYS®) with Osimertinib (TAGRISSO®) as a first-line treatment option for specific patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) mutations and MET overexpression. The final patient was enrolled on August 18, 2025. The primary outcomes of the SANOVO study are anticipated to be released in the second half of 2026 and will be presented at pertinent academic conferences. Should the study yield favorable results, Chi-Med intends to submit an application to the National Medical Products Administration for the approval of a novel indication.
-
C114 Communication Network -
Communication Home
